Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Why BioNTech Stock Soared Today
Why BioNTech Stock Soared Today

BioNTech (NASDAQ: BNTX), one of the companies made famous for its role developing vaccines with Pfizer (NYSE: PFE) during the COVID-19 pandemic, soared 20.2% through 12:50 p.m. Monday on news

The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip

Even though broader equities have been highly volatile this year, it's still a good idea to invest in stocks for a straightforward reason. Holding shares of top companies for five years and beyond

3 No-Brainer Healthcare Stocks to Buy in June
3 No-Brainer Healthcare Stocks to Buy in June

A new month has arrived. Investors now have a fresh opportunity to buy great stocks. Three Motley Fool contributors believe they've found no-brainer healthcare stocks to buy in June. Here's why they

Could Viking Therapeutics Become the Next Eli Lilly?
Could Viking Therapeutics Become the Next Eli Lilly?

The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering transformative patient results and powering its stock to a spectacular 400% return

Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?

Shares of Summit Therapeutics (NASDAQ: SMMT) tanked more than 30% on Friday, May 30. Such dramatic price swings aren't unusual in the biotechnology industry; in this case, disappointing data from an

EQS-News: Gerresheimer Adjusts Guidance for Financial Year 2025
EQS-News: Gerresheimer Adjusts Guidance for Financial Year 2025
EQS-News: Gerresheimer Adjusts Guidance for Financial Year 2025
EQS-Adhoc: Gerresheimer AG: Adjustment of Guidance for 2025
EQS-Adhoc: Gerresheimer AG: Adjustment of Guidance for 2025
EQS-Adhoc: Gerresheimer AG: Adjustment of Guidance for 2025
EQS-News: Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) of the Regulation (EU) No 596/2014 and Art. 2 (1) of the Delegated Regulation (EU) 2016/1052 of the Commission
EQS-News: Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) of the Regulation (EU) No 596/2014 and Art. 2 (1) of the Delegated Regulation (EU) 2016/1052 of the Commission
EQS-News: Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) of the Regulation (EU) No 596/2014 and Art. 2 (1) of the Delegated Regulation (EU) 2016/1052 of the Commission
Terrible News for Pfizer Stock Investors
Terrible News for Pfizer Stock Investors

The past three years have been challenging for Pfizer (NYSE: PFE). Revenue and earnings have moved in the wrong direction, as has the company's share price. The stock is down by 56% since 2022

Here's How Many Shares of AT&T You Must Own to Make $5,000 in Annual Dividend Income
Here's How Many Shares of AT&T You Must Own to Make $5,000 in Annual Dividend Income

More than 100 million Americans use AT&T's (NYSE: T) products and services. So do nearly 2.5 million businesses. How many investors rely on A&T's stock to generate reliable dividend income? I don't

Beat the S&P 500 With This Cash-Gushing Dividend Stock
Beat the S&P 500 With This Cash-Gushing Dividend Stock

You don't need to uncover the next big artificial intelligence stock to outperform the broader stock market. Sometimes, consistent and profitable growth is all you need to achieve outsize investment

Does This Move Make Medtronic Stock a Buy?
Does This Move Make Medtronic Stock a Buy?

Over the past few years, Medtronic (NYSE: MDT) has faced significant challenges, including a pandemic-induced slowdown, relatively slow revenue growth, and economic issues that impacted its

The Smartest Growth Stock to Buy With $5,000 Right Now
The Smartest Growth Stock to Buy With $5,000 Right Now

Investors tend to gravitate to growth stocks they perceive as smart. Indeed, the idea of a smart stock can depend heavily on one's point of view.

Still, most would agree that buying a wonderful

Why Summit Therapeutics Plunged Today
Why Summit Therapeutics Plunged Today

Shares of Summit Therapeutics (NASDAQ: SMMT) have plunged 31% as of 1:23 p.m. ET Friday, following the release of some trial data this morning.

Summit has been a tremendous winner over the past

2 Top Stocks to Buy With Less Than $100
2 Top Stocks to Buy With Less Than $100

When investing on a budget, buying fractional shares of top companies is one option. Another is to find stocks with relatively affordable price tags per share. Although it's sometimes the case that

1 Thing Investors Must Know Before Buying the 52% Dip on UnitedHealth Group
1 Thing Investors Must Know Before Buying the 52% Dip on UnitedHealth Group

UnitedHealth Group (NYSE: UNH) is central to the trillion-dollar U.S. healthcare industry. It's a behemoth that generates over $400 billion in annual revenue with insurance, pharmacy, care services

EQS-News: STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2025
EQS-News: STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2025
EQS-News: STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2025
Should You Buy AMD Stock Before June 12?
Should You Buy AMD Stock Before June 12?

In this video, I will cover the recent updates regarding Advanced Micro Devices (NASDAQ: AMD). Watch the short video to learn more, consider subscribing, and click the special offer link below.

UnitedHealth Group Stock Is Near 5-Year Lows: Is It a Bargain Buy?
UnitedHealth Group Stock Is Near 5-Year Lows: Is It a Bargain Buy?

UnitedHealth Group (NYSE: UNH) is one of the biggest health insurers in the U.S. It plays a critical role in the healthcare industry, and for years, it has been a sound stock to invest in.

This

The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move.
The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move.

Earlier this year, biotech company 23andMe filed for bankruptcy. The harsh reality was that its business, while enticing to people who wanted to learn about their backgrounds via DNA testing kits

Is Amgen Stock a Buy?
Is Amgen Stock a Buy?

Amgen (NASDAQ: AMGN) is doing something unusual in 2025. The biotech giant's shares are up 7.2% for the year as I write this while most large-cap healthcare stocks struggle; yet it trades at just 13

EQS-Adhoc: Biotest AG: Change of the Chief Executive Officer (CEO) of Biotest AG
EQS-Adhoc: Biotest AG: Change of the Chief Executive Officer (CEO) of Biotest AG
EQS-Adhoc: Biotest AG: Change of the Chief Executive Officer (CEO) of Biotest AG
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow

The three major indexes slid in March and April as investors worried about the impact of President Donald Trump's import tariffs on the economy -- but in recent weeks, optimism about lower, more

Why Semiconductor Stocks Broadcom, AMD, and Arm Holdings Rallied Today
Why Semiconductor Stocks Broadcom, AMD, and Arm Holdings Rallied Today

Shares of major semiconductor stocks Broadcom (NASDAQ: AVGO), Advanced Micro Devices (NASDAQ: AMD), and Arm Holdings (NASDAQ: ARM) rallied on Tuesday, rising 3%, 3.9%, and 5.3%, respectively.

Chip

Is Pfizer Stock a Buy After This $1.25 Billion Investment?
Is Pfizer Stock a Buy After This $1.25 Billion Investment?

Pfizer (NYSE: PFE) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.

However